By Angela McDaniels
Seattle, Feb. 1 - Ulysses Pharmaceuticals has received C$1 million each from Fonds Bio-Innovation LP and BDC Venture Capital, according to a company news release.
Proceeds will be used for preclinical development of new antibiotic molecules the firm has identified, synthesized and patented for the treatment of severe and recurring infectious human diseases.
The antibiotic molecules have antibacterial properties that are potentially superior to the anti-infectious agents currently on the market, according to the release.
"[These] discoveries indicate the firm's tremendous potential for innovation and growth and help give Ulysses a leading position in the fast-growing field of antibiotic research and development," Réjean Asselin, director of technology seed investments at BDC, said in the release.
Ulysses is biopharmaceutical company based in Sherbrooke, Quebec.
| Issuer: | Ulysses Pharmaceuticals
|
| Issue: | Private financing
|
| Amount: | C$2 million
|
| Investors: | Fonds Bio-Innovation LP, BDC Venture Capital
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
